Advertisement

Investigational New Drugs

, Volume 31, Issue 6, pp 1587–1591 | Cite as

Phase I/II trial of pemetrexed plus nab-paclitaxel in advanced solid tumor patients with emphasis on non-small cell lung cancer

  • Cheryl HoEmail author
  • Angela M. Davies
  • Randeep S. Sangha
  • Derick Lau
  • Primo LaraJr.
  • Helen K. Chew
  • Laurel Beckett
  • Philip C. Mack
  • Jonathan W. Riess
  • David R. Gandara
PHASE II STUDIES

Summary

Background Despite advances in targeted therapies, there is an ongoing need to develop new and effective cytotoxic drug combinations in non-small cell lung cancer (NSCLC). Based on preclinical demonstration of additive cytotoxicity, we evaluated the safety and efficacy of combining pemetrexed and nanoparticle albumin bound (nab) paclitaxel with a focus on NSCLC for phase II expansion. Methods A 3 + 3 dose-escalation design was used to determine the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D). Three dose levels were tested: pemetrexed 500 mg/m2 day 1 and nab-paclitaxel day 1 at 180, 220, & 260 mg/m2 every 21 days. Phase II eligibility included advanced NSCLC, ≤2 line prior therapy, PS 0–1, adequate organ function. Primary endpoint for further study was response rate (RR) ≥ 25 %. Results Planned dose escalation was completed without reaching the MTD. The RP2D was pemetrexed 500 mg/m2 and nab-paclitaxel 260 mg/m2. The phase II portion accrued 37 pts before early closure due to increasing first-line pemetrexed/platinum doublet use in non-squamous NSCLC. In 31 assessable phase II patients there were 5 partial responses, 12 stable disease, 14 progressive disease. The median overall survival was 8.8 months; progressive disease 4.4 months and disease control 15.6 months. Conclusions Pemetrexed 500 mg/m2 day 1 with nab-paclitaxel 260 mg/m2 was feasible and well tolerated. The phase II component demonstrated activity in second/third-line therapy of advanced NSCLC; response rate 14 % and disease control rate 46 %. Treatment practice patterns of advanced NSCLC have evolved; further trials of this regimen are not planned.

Keywords

Phase II Pemetrexed Nab-paclitaxel Nanoparticle albumin bound paclitaxel Non small cell lung cancer 

Notes

Acknowledgments

The authors are thankful for the expert administrative support of Grace Loredo in conducting this study.

Research support

Support for this trial was provided by the UC Davis Cancer Center, Eli Lilly and Company and Abraxis BioScience (a wholly-owned subsidiary of Celgene Corporation).

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    American Cancer Society (2013) Cancer facts and figures 2013. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf. Accessed Jul 2013
  2. 2.
    Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26(21):3543–3551CrossRefPubMedGoogle Scholar
  3. 3.
    Mok TS, Wu Y, Thongprasert S, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947–957Google Scholar
  4. 4.
    Ciuleanu T, Brodowicz T, Zielinski C et al (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374:1432–1440CrossRefPubMedGoogle Scholar
  5. 5.
    Fossella FV, DeVore R, Kerr RN et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18:2354–2362PubMedGoogle Scholar
  6. 6.
    Shepherd FA, Dancey J, Ramlau R et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.[comment]. J Clin Oncol 18:2095–2103PubMedGoogle Scholar
  7. 7.
    Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132CrossRefPubMedGoogle Scholar
  8. 8.
    Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589–1597CrossRefPubMedGoogle Scholar
  9. 9.
    Eli Lilly and Company (2012) ALIMTA full prescribing information. http://pi.lilly.com/us/alimta-pi.pdf. Accessed Jul 2013
  10. 10.
    Celgene Corporation (2012) ABRAXANE full prescribing information http://www.abraxane.com/downloads/Abraxane_PrescribingInformation.pdf. Accessed Jul 2013
  11. 11.
    Socinski MA, Bondarenko I, Karaseva NA et al (2012) Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 30:2055–2062CrossRefPubMedGoogle Scholar
  12. 12.
    Teicher BA, Alvarez E, Liu P et al (1999) MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma. Semin Oncol 26:55–62PubMedGoogle Scholar
  13. 13.
    Teicher BA, Chen V, Shih C et al (2000) Treatment regimens including the multitargeted antifolate LY231514 in human tumor xenografts. Clin Cancer Res 6:1016–1023PubMedGoogle Scholar
  14. 14.
    Kano Y, Akutsu M, Tsunoda S et al (2004) Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro. Cancer Chemother Pharmacol 54:505–513CrossRefPubMedGoogle Scholar
  15. 15.
    US Department of Health and Human Services (2003) Common terminology criteria for adverse events (CTCAE) version 3.0. National Institutes of Health, National Cancer InstituteGoogle Scholar
  16. 16.
    Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. Journal of the National Cancer Institute 92:205–216CrossRefPubMedGoogle Scholar
  17. 17.
    Stathopoulos GP, Dimitroulis J, Toubis M et al (2007) Pemetrexed combined with paclitaxel in patients with advanced or metastatic non-small-cell lung cancer: a phase I-II trial. Lung Cancer 57:66–71CrossRefPubMedGoogle Scholar
  18. 18.
    Kosmidis P, Mylonakis N, Skarlos D et al (2000) Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Ann Oncol 11:799–805CrossRefPubMedGoogle Scholar
  19. 19.
    Hanauske AR, Dumez H, Piccart M et al (2009) Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors. Invest New Drugs 27:356–365CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Cheryl Ho
    • 1
    Email author
  • Angela M. Davies
    • 2
  • Randeep S. Sangha
    • 4
  • Derick Lau
    • 3
  • Primo LaraJr.
    • 3
  • Helen K. Chew
    • 3
  • Laurel Beckett
    • 3
  • Philip C. Mack
    • 3
  • Jonathan W. Riess
    • 3
  • David R. Gandara
    • 3
  1. 1.British Columbia Cancer AgencyVancouverCanada
  2. 2.NovocureNew YorkUSA
  3. 3.University of California Davis Medical CenterSacramentoUSA
  4. 4.Cross Cancer InstituteEdmontonCanada

Personalised recommendations